A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With a Polyvalent Vaccine-KLH Conjugate [cancer vaccines] + OPT-821 Versus OPT-821.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs OPT 821 (Primary) ; Polyvalent antigen-KLH conjugate vaccine (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Feb 2020 Biomarkers information updated
- 08 Apr 2013 Actual initiation date Aug 2008 added as reported by ClinicalTrials.gov.
- 01 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.